JP2011500780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500780A5 JP2011500780A5 JP2010530564A JP2010530564A JP2011500780A5 JP 2011500780 A5 JP2011500780 A5 JP 2011500780A5 JP 2010530564 A JP2010530564 A JP 2010530564A JP 2010530564 A JP2010530564 A JP 2010530564A JP 2011500780 A5 JP2011500780 A5 JP 2011500780A5
- Authority
- JP
- Japan
- Prior art keywords
- bosentan
- crystal form
- until
- solid
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 45
- 229960003065 bosentan Drugs 0.000 claims 45
- 239000007787 solid Substances 0.000 claims 23
- 239000013078 crystal Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 19
- 239000002904 solvent Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 12
- 238000001914 filtration Methods 0.000 claims 10
- 238000001035 drying Methods 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 238000001816 cooling Methods 0.000 claims 8
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims 8
- 239000002244 precipitate Substances 0.000 claims 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
- 239000000725 suspension Substances 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 4
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 238000003756 stirring Methods 0.000 claims 4
- 102000010180 Endothelin receptor Human genes 0.000 claims 3
- 108050001739 Endothelin receptor Proteins 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000706 filtrate Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000001376 precipitating effect Effects 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2108MU2007 | 2007-10-24 | ||
| PCT/GB2008/050986 WO2009053748A2 (en) | 2007-10-24 | 2008-10-24 | Novel crystalline forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500780A JP2011500780A (ja) | 2011-01-06 |
| JP2011500780A5 true JP2011500780A5 (enExample) | 2011-12-08 |
Family
ID=40262729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530564A Pending JP2011500780A (ja) | 2007-10-24 | 2008-10-24 | 新規結晶形 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8530488B2 (enExample) |
| EP (1) | EP2222649A2 (enExample) |
| JP (1) | JP2011500780A (enExample) |
| CN (1) | CN101939303B (enExample) |
| AU (1) | AU2008315757A1 (enExample) |
| CA (1) | CA2703230A1 (enExample) |
| NZ (2) | NZ600010A (enExample) |
| WO (1) | WO2009053748A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2686457A1 (en) * | 2007-05-08 | 2008-11-13 | Generics [Uk] Limited | Novel polymorphic forms |
| CA2694242C (en) * | 2007-06-29 | 2013-10-01 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
| US8530488B2 (en) * | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| JP5535082B2 (ja) * | 2008-01-01 | 2014-07-02 | シプラ・リミテッド | ボセンタン、その多形形態及びその塩の合成方法 |
| WO2009093127A2 (en) | 2008-01-24 | 2009-07-30 | Actavis Group Ptc Ehf | Substantially pure and a stable crystalline form of bosentan |
| AU2009211159B2 (en) | 2008-02-08 | 2013-02-07 | Generics [Uk] Limited | Process for preparing bosentan |
| EP2331513A1 (en) | 2008-08-12 | 2011-06-15 | Cadila Healthcare Limited | Process for preparation of bosentan |
| NZ593117A (en) | 2008-11-03 | 2013-03-28 | Generics Uk Ltd | HPLC METHOD FOR THE ANALYSIS OF BOSENTAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS Chromatography mass spectrometry fragmentation |
| WO2012002547A1 (ja) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | ボセンタン固体分散体 |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| PL402305A1 (pl) * | 2012-12-30 | 2014-07-07 | Instytut Farmaceutyczny | Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570699B1 (fr) * | 1984-09-24 | 1987-08-28 | Roussel Uclaf | Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5276004A (en) * | 1987-03-20 | 1994-01-04 | Dai Nippon Insatsu Kabushiki Kaisha | Process for heat transfer recording |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| US6136971A (en) * | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
| SI1535613T1 (sl) | 1999-11-17 | 2010-12-31 | Teva Pharma | Postopek za pripravo polimorfne oblike atorvastatin kalcija |
| CN1411373A (zh) | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
| ES2255973T3 (es) * | 2000-01-25 | 2006-07-16 | F. Hoffmann-La Roche Ag | Preparacion de sulfonamidas. |
| US6479692B1 (en) | 2001-05-02 | 2002-11-12 | Nobex Corporation | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
| AU2003209669A1 (en) | 2003-02-25 | 2004-09-17 | Hetero Drugs Limited | Amorphous form of losartan potassium |
| EP1603920A1 (en) | 2003-03-12 | 2005-12-14 | Cadila Healthcare Ltd. | Polymorph and amorphous form of (s)-(+)-clopidogrel bisulfate |
| AU2003230195A1 (en) | 2003-04-02 | 2004-10-25 | Hetero Drugs Limited | A novel process for amorphous form of donepezil hydrochloride |
| US20080188663A1 (en) * | 2007-01-29 | 2008-08-07 | Ashok Kumar | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I |
| WO2008122020A1 (en) * | 2007-04-02 | 2008-10-09 | Auspex Pharmaceuticals, Inc. | Substituted pyrimidines |
| CA2686457A1 (en) * | 2007-05-08 | 2008-11-13 | Generics [Uk] Limited | Novel polymorphic forms |
| CA2694242C (en) | 2007-06-29 | 2013-10-01 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
| WO2009047637A1 (en) | 2007-10-11 | 2009-04-16 | Actavis Group Ptc Ehf | Novel polymorphs of bosentan |
| US8530488B2 (en) * | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| ATE530531T1 (de) | 2007-12-18 | 2011-11-15 | Dipharma Francis Srl | Verfahren zur herstellung von bosentan |
| WO2009095933A2 (en) | 2008-01-10 | 2009-08-06 | Msn Laboratories Limited | Improved and novel process for the preparation of bosentan |
| WO2009093127A2 (en) | 2008-01-24 | 2009-07-30 | Actavis Group Ptc Ehf | Substantially pure and a stable crystalline form of bosentan |
| AU2009211159B2 (en) | 2008-02-08 | 2013-02-07 | Generics [Uk] Limited | Process for preparing bosentan |
| EP2268634A2 (en) | 2008-03-13 | 2011-01-05 | Actavis Group PTC EHF | Processes for the preparation of bosentan and related compounds using novel intermediates |
| EP2294056A1 (en) | 2008-05-23 | 2011-03-16 | Synthon B.V. | Bosentan salts |
| NZ593117A (en) | 2008-11-03 | 2013-03-28 | Generics Uk Ltd | HPLC METHOD FOR THE ANALYSIS OF BOSENTAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS Chromatography mass spectrometry fragmentation |
| IT1393136B1 (it) | 2009-03-11 | 2012-04-11 | Sifa Vitor S R L | Procedimento per la preparazione del bosentan |
-
2008
- 2008-10-24 US US12/739,303 patent/US8530488B2/en not_active Expired - Fee Related
- 2008-10-24 EP EP08806793A patent/EP2222649A2/en not_active Withdrawn
- 2008-10-24 AU AU2008315757A patent/AU2008315757A1/en not_active Abandoned
- 2008-10-24 NZ NZ600010A patent/NZ600010A/xx not_active IP Right Cessation
- 2008-10-24 CN CN200880122464.2A patent/CN101939303B/zh not_active Expired - Fee Related
- 2008-10-24 WO PCT/GB2008/050986 patent/WO2009053748A2/en not_active Ceased
- 2008-10-24 NZ NZ585438A patent/NZ585438A/xx not_active IP Right Cessation
- 2008-10-24 CA CA2703230A patent/CA2703230A1/en not_active Abandoned
- 2008-10-24 JP JP2010530564A patent/JP2011500780A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500780A5 (enExample) | ||
| CN103664921B (zh) | 一种阿齐沙坦晶型a及其制备方法 | |
| CN104860894A (zh) | 一种抗心衰药lcz696的制备方法 | |
| CN101983195A (zh) | 新型多晶型物及其制备方法 | |
| JP2019505532A5 (enExample) | ||
| EP2150547A2 (en) | Polymorphic forms of bosentan | |
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| US20090281315A1 (en) | Forms of lapatinib ditosylate and processes for preparation thereof | |
| CN114746412A (zh) | Kd-025的新晶型及其制备方法 | |
| CN102639522A (zh) | 3-(4-氨基-1-氧代-1, 3-二氢-异吲哚-2-基)-哌啶-2, 6-二酮的固体形式及制备它们的方法 | |
| EP2584901A1 (en) | A process for etra virine intermediate and polymorphs of etravirine | |
| CN112142604A (zh) | 一种盐酸溴己新及其中间体的制备方法 | |
| JP2013503173A5 (enExample) | ||
| WO2012037764A1 (zh) | （e）-2-[2-（6-氯嘧啶-4-基氧）苯基]-3-甲氧基丙烯酸甲酯的制备方法 | |
| CN101928277B (zh) | 4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]安息香酸的制备方法、相关中间体及其应用 | |
| CN110092786B (zh) | 吴茱萸碱的制造方法 | |
| CN103360381B (zh) | 阿齐沙坦的新晶型及其制备方法和应用 | |
| CN103772413B (zh) | 一种利福平ⅱ晶型的制备方法 | |
| CN112028896A (zh) | 阿卡替尼的新晶型及其制备方法 | |
| WO2012168948A2 (en) | Process for febuxostat | |
| CN102746283A (zh) | 高纯度水飞蓟宾的制备方法 | |
| WO2024094110A1 (zh) | 一种替马他赛化合物晶型及其制备方法和用途 | |
| WO2014195977A2 (en) | Novel polymorphs of vismodegib | |
| CN102838594A (zh) | 一种达沙替尼的制备及精制方法 | |
| EP2619191A2 (en) | Novel polymorphs of febuxostat |